26rhk062 10.3205/26rhk062 urn:nbn:de:0183-26rhk0628 Meeting Abstract Monnard Monnard Arnaud A

Eli Lilly Suisse SA, Vernier, Schweiz

author Rößler Rößler Tatjana T

Lilly Deutschland GmbH, Bad Homburg, Deutschland

author Nissen Nissen Michael J. MJ

Geneva University Hospital, Geneva, Schweiz

author Möller Möller Burkhard B

Inselspital, Universitätsspital Bern, Deutschland

author Kyburz Kyburz Diego D

Universitätsspital Basel, Basel, Schweiz

author Ciurea Ciurea Adrian A

Universitätsspital Zürich, Zürich, Schweiz

author Rubbert-Roth Rubbert-Roth Andrea A

Universitätsspital Zürich, Zürich, Schweiz

author Rodrigues Rodrigues Claudia Lourenço CL

Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) Foundation, Zürich, Schweiz

author Tamborrini Tamborrini Giorgio G

uzr.swiss, Basel, Schweiz

author Micheroli-Konuk Micheroli-Konuk Raphael R

Universitätsspital Zürich, Zürich, Schweiz

author German Medical Science GMS Publishing House

Düsseldorf

610 20260909 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0656 062 Deutsche Gesellschaft für Rheumatologie Deutsche Gesellschaft für Orthopädische Rheumatologie Gesellschaft für Kinder- und Jugendrheumatologie 54. Kongress der Deutschen Gesellschaft für Rheumatologie und Klinische Immunologie (DGRh), 36. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR), 40. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh) Deutscher Rheumatologiekongress 2026 Epidemiologie & Versorgungsforschung Leipzig 20260909 20260912 EV.11 TextIntroduction: Obesity represents a frequent comorbidity in psoriatic arthritis (PsA), linked to increased disease burden and cardiometabolic risk. Real-world data on the prevalence, clinical characteristics, and socioeconomic determinants of overweight/obesity in PsA patients remain limited in European countries.Methods: This retrospective, cross-sectional analysis utilized data from the Swiss Clinical Quality Management (SCQM) PsA registry. Adult PsA patients with ≥1 registry visit between January 1, 2017 and December 1, 2025 were eligible. Body mass index (BMI) categories were defined per World Health Organization (WHO) criteria in kg/m²: underweight (<18.5), normal weight (18.5–24.9), overweight (25.0–29.9), and obesity (≥30.0; class I 30.0–34.9, class II 35.0–39.9, class III ≥40.0). Prevalence estimates of BMI categories among PsA patients with 95% confidence intervals (CIs) were calculated descriptively. Associations between overweight/obesity (BMI ≥25 kg/m²) and demographic or sociodemographic characteristics were explored using univariate logistic regression.Results: A total of 2,087 PsA patients with available BMI data were included. Overall, 36.0% were living with overweight and 27.6% with obesity (class I 18.0%, class II 6.8%, class III 2.9%). Women had a higher prevalence of obesity (28.9% vs. 26.4%) and men of overweight (41.6% vs. 30.7%) (Figure 1 ).Cardiometabolic comorbidities (cardiovascular disease, type 2 diabetes, hypertension, hyperlipidemia) and depression were more frequent with higher BMI. Disease activity and inflammatory markers increased with higher BMI categories; further clinical characteristics are shown in Table 1 . In univariate logistic regression for BMI ≥25 kg/m², increasing age (odds ratio (OR) 1.02; 95% CI 1.01–1.03; p<0.001), male sex (OR 1.44; 95% CI 1.21–1.73; p<0.001), and residence in the Mittelland region (OR 1.58; 95% CI 1.10–2.27; p=0.014) were associated with higher odds of overweight/obesity, whereas tertiary education was inversely associated (OR 0.44; 95% CI 0.31–0.62; p<0.001). Occupation was not significantly associated.Conclusion: In this Swiss PsA cohort, over 60% were living with overweight (36.0%) or obesity (27.6%), substantially higher than in the general Swiss population (31% and 12%, respectively) . Higher BMI categories were accompanied by greater disease activity, cardiometabolic burden, and depression. These findings underscore the need for weight and comorbidity management in routine PsA care.Disclosures: Arnaud Monnard and Tatjana Rößler are employees and minor shareholders of Eli Lilly and Company. Michael J. Nissen: Speaker and/or consultancy fees (paid to Institution) from AbbVie, Novartis, Pfizer, Eli Lilly, and Janssen. Burkhard Moeller: Speakers fee, travel reimbursement and advisory board activities from UCB, Novartis. Diego Kyburz: Speaker or consultant: Abbvie, Janssen, Novartis, UCB, Eli-Lilly, Pfizer, Johnson&Johnson. Adrian Ciurea: No conflicts of interest related to this work. Andrea Rubbert-Roth: Speaker and/or consultation fees from Abbvie, Roche, Pfizer, Novartis, Eli Lilly, Janssen, UCB, Sanofi. Claudia Lourenço Rodrigues: No conflicts of interest related to this work. G Tamborrini: No conflicts of interest related to this work. Raphael Micheroli-Konuk: Speaker fees from Eli Lilly, UCB, JnJ and AbbVie. Federal Statistic Office Swiss Health Survey 2022: overweight and obesity Federal Statistic Office. Swiss Health Survey 2022: overweight and obesity. [Last accessed: 2026 Mar]. Available from: https://www.bfs.admin.ch/bfs/en/home.gnpdetail.2024-0164.html https://www.bfs.admin.ch/bfs/en/home.gnpdetail.2024-0164.html 11

Table 1: Baseline demographic, clinical, and quality of life characteristics among PsA patients living with normal weight (BMI 18.5–24.9 kg/m²), overweight (BMI 25.0–29.9 kg/m²) and obesity (BMI =30.0 kg/m²)

1

1 1 Figure 1: Baseline prevalence of BMI categories (in kg/m²) among PsA patients

1 0 0